DC
XFOR icon

Diametric Capital’s X4 Pharmaceuticals XFOR Stock Holding History

Diametric Capital’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,973
Closed -$120K – 709
2026
Q1 		$120K Buy
+28,973
New +$109K 0.03% 413
2024
Q4 		– Sell
-9,618
Closed -$193K – 465
2024
Q3 		$193K Sell
9,618
-5,335
-36% -$111K 0.1% 311
2024
Q2 		$260K Buy
+14,953
New +$489K 0.14% 206

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Diametric Capital's XFOR Position: Q2 2026 in Review

Diametric Capital sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 28,973 shares — an estimated $120K sold.

Diametric Capital first reported a position in XFOR in Q2 2024 and held it in 3 quarters. The position peaked at $260K in Q2 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Diametric Capital reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 28,973 X4 Pharmaceuticals shares in Q2 2026, an estimated $120K.
  • Diametric Capital first reported a position in X4 Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Diametric Capital's X4 Pharmaceuticals position peaked at $260K in Q2 2024.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.